Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Imviva Biotech

News headline image
Imviva Biotech Presents Studies on CTD402 Allogeneic CAR-T Therapy at EHA2026 Congress
From Imviva Biotech
Via GlobeNewswire
News headline image
Imviva Biotech Receives FDA Investigational New Drug Approval for CTA313, a Dual-Targeted CD19/BCMA Allogeneic CAR-T Cell Therapy for Autoimmune Diseases
From Imviva Biotech
Via GlobeNewswire
News headline image
Imviva Biotech to Present Data from Clinical Studies of CTA313 and CTD402 Validating its ANSWER™ Allogeneic CAR-T Platform in Pediatric and Adult Patient Populations at EULAR and EHA 2026 Congresses
From Imviva Biotech
Via GlobeNewswire
News headline image
Imviva Biotech Presents Data Demonstrating Durable Clinical Responses from Ongoing Phase 1/2 Study of CTA313 in Systemic Lupus Erythematosus at ASGCT 2026
From Imviva Biotech
Via GlobeNewswire
News headline image
Imviva Biotech to Present Clinical Data from Ongoing Phase 1/2 Study of CTA313 at the American Society of Gene & Cell Therapy's Annual Meeting
From Imviva Biotech
Via GlobeNewswire
News headline image
Imviva Biotech Announces Acceptance of Late-Breaking Abstract Highlighting Data from Ongoing Phase 1/2 Study of CTA313 at 15th European Lupus Meeting
From Imviva Biotech
Via GlobeNewswire
News headline image
Imviva Biotech Receives FDA Orphan Drug Designation for CTD402 for the Treatment of T-Cell Leukemia and Lymphoma
From Imviva Biotech
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.